## Dorianna SandonÃ

## List of Publications by Year

 in descending orderSource: https:||exaly.com/author-pdf/7137220/publications.pdf
Version: 2024-02-01

| 35 | citations |
| :---: | :---: | :---: | :---: | :---: |
| papers |  |
| all docs |  |

```
Stimulation of P2 receptors causes release of IL-1 1`2â€"loaded microvesicles from human dendritic cells.
Blood, 2007, 109, 3856-3864.
1.4

6 Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects. Expert Reviews in Molecular
Medicine, 2009, 11, e28.
\begin{tabular}{|c|c|c|c|}
\hline 11 & \begin{tabular}{l}
Inhibition of Proteasome Activity Promotes the Correct Localization of Disease-Causing \(\hat{\underline{l}} \pm\)-Sarcoglycan \\
 Pathology, 2008, 173, 170-181.
\end{tabular} & 3.8 & 48 \\
\hline 12 & The Tâ€tubule membrane ATPâ€operated P2X 4 receptor influences contractility of skeletal muscle. FASEB Journal, 2005, 19, 1184-1186. & 0.5 & 42 \\
\hline 13 & Evidence for the Presence of Two Homer 1 Transcripts in Skeletal and Cardiac Muscles. Biochemical and Biophysical Research Communications, 2000, 279, 348-353. & 2.1 & 39 \\
\hline
\end{tabular}

14 Characterization of the ATP-hydrolysing activity of \(\hat{I}_{ \pm}-\)sarcoglycan. Biochemical Journal, 2004, 381,

2.4

22
Biophysica Acta Gene Regulatory Mechanisms, 1991, 1129, 100-104.
20 Subcellular distribution of Homer 1b/c in relation to endoplasmic reticulum and plasma membrane
3.3

20 proteins in Purkinje neurons. Neurochemical Research, 2003, 28, 1151-1158.
21 Expression of Cytochrome c Oxidase during Growth and Development of Dictyostelium. Journal of
3.4

Biological Chemistry, 1995, 270, 5587-5593.
19

22 Repairing folding-defective ît-sarcoglycan mutants by CFTR correctors, a potential therapy for
2.9
limb-girdle muscular dystrophy 2D. Human Molecular Genetics, 2018, 27, 969-984.
19

23 Nonâ€genomic mechanisms in the estrogen regulation of glycolytic protein levels in endothelial cells.
\(0.5 \quad 18\)

Transition of Homer isoforms during skeletal muscle regeneration. American Journal of Physiology -
Cell Physiology, 2006, 290, C711-C718.
4.6

\(3.4 \quad 14\)
Chemistry, 2014, 289, 33073-33082.

26 Novel aspects of chlorophyll a/b-binding proteins. Physiologia Plantarum, 1997, 100, 769-779.
5.2 common ancestor. FEBS Letters, 1990, 261, 158-160.

1st International Workshop on Clinical trial readiness for sarcoglycanopathies 15 â€" 16 November 2016,
Evry, France. Neuromuscular Disorders, 2017, 27, 683-692.
0.6

9
28 Evry, France. Neuromuscular Disorders, 2017, 27, 683-692.

> Targeting of PFKFB3 with miRâ€206 but not mirâ€26b inhibits ovarian cancer cell proliferation and
> migration involving FAK downregulation. FASEB Journal, 2022, 36, e22140.

Inhibition of the synthesis of a cytochrome-c-oxidase subunit isoform by antisense RNA. FEBS Journal,
30 1994, 219, 1053-1061.
0.2
0.5

9

CFTR corrector C17 is effective in muscular dystrophy, <i>in vivo</i> proof of concept in LGMDR3.
Human Molecular Genetics, 2022, 31, 499-509.

Emerging therapeutic strategies for sarcoglycanopathy. Expert Opinion on Orphan Drugs, 2017, 5, 381-396.

33 Combined Use of CFTR Correctors in LGMD2D Myotubes Improves Sarcoglycan Complex Recovery.
International Journal of Molecular Sciences, 2020, 21, 1813.
4.1

6

Customized bioreactor enables the production of 3D diaphragmatic constructs influencing matrix
remodeling and fibroblast overgrowth. Npj Regenerative Medicine, 2022, 7, 25.```

